

Supplementary Figure S2. Effect of AAV-sTRAIL vector in mice bearing U87 glioma tumors. 10⁵ U87-Fluc/NF-Gluc cells were implanted intracranially and 19 days later, mice were randomized into two groups (n=5/group) and infused into the same injection site as tumor with either AAV-Vluc/GFP or AAV-Vluc/sTRAIL. (a) Mice were imaged weekly over 3 weeks post-vector injection. Representative mice are shown for both groups at each time point. Star represents control AAV-Vluc/GFP mice which were sacrificed due to tumor burden. Note the different bioluminescent signal scale for each imaging time point in order to show tumor location. (b) Quantitation of tumor-associated Fluc signal in mice from (a). The arrow indicates mice sacrifice at week 2 post-vector injection due to tumor size.